Module 2 lecture 1 Flashcards
define pre menopausal, perimenopausal and post menopausal
Pre menopausal- time period of endocrine changes before cessation of menstruation
perimenopausal- The period of endocrine changes surrounding menopause
postmenopausal- The time period of endocrine changes surrounding menopause
What are some clinical representations of menopause
Hot flashes
Night sweats
sleep disturbances
vaginal dryness
mood changes
Absolute contraindications to menopausal hormone therapy
pregnancy
Endometrial or breast cancer
stroke
Active thromboembolic disorders
active liver disease
Estrogen monotherapy principle
estrogen monotherapy is only for women without a uterus
Why is estrogen monotherapy used in women without uteruses
They do not have to worry about endometrial cancer
Name 4 estrogen monotherapy drug ROA
Oral
topical
transdermal
Intravaginal
Intramuscular
Name 3 oral estrogen monotherapy drugs
Premarin, estraca and menest
Why do oral estrogen monotherapy drugs have more sideeffects
1st pass metabollism
Name estrogen monotherapy transdermal products
Vivelle-dot, vivelle, Alora, climara, menostar, minivelle
Why are transdermal products favored?
Less side effects, less risk of stroke and thromboembolism
What are some characteristics of intravaginal products for estrogen monotherapy
minimal systemic absorption (except for 1 exception)
helps vaginal dryness
What is the only intravaginal estrogen monotherapy that is systemically absorbed
Femring.
can we give women with uterus intact intravaginal products? Why?
What intravaginal product will require us to give her progesterone
We can usually give wome with uterus intact intravaginal products. This is due to their minimal systemic absorption in the body. The exception to this ofcourse is femring. We will need to give progesterone along with that product.
Name IM estrogen monotherapy drugs
Estradiol cypionate
Estradiol Valerate
Which drugs should be prescribed for women experiencing vaginal dryness
Topical vaginal products
Women with uterus intact should be prescribed a __________ in addition to estrogen to decrease risk of endometrial cancer
progestin